Bridgeway Capital Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Bridgeway Capital Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-65,900	Closed	-$21.5K	–	1451
2023 Q2	$21.5K	Hold	65,900	–	–	﹤0.01%	1361
2023 Q1	$28.3K	Sell	65,900 -50,000	-43%	-$26.4K	﹤0.01%	1346
2022 Q4	$61.4K	Hold	115,900	–	–	﹤0.01%	1280
2022 Q3	$85K	Sell	115,900 -50,000	-30%	-$56.7K	﹤0.01%	1303
2022 Q2	$189K	Sell	165,900 -10,000	-6%	-$12.7K	﹤0.01%	1102
2022 Q1	$361K	Sell	175,900 -21,700	-11%	-$51.6K	0.01%	1021
2021 Q4	$569K	Sell	197,600 -50,000	-20%	-$185K	0.01%	943
2021 Q3	$1.05M	Buy	247,600 +98,000	+66%	+$437K	0.02%	810
2021 Q2	$791K	Buy	149,600 +12,200	+9%	+$58.7K	0.01%	933
2021 Q1	$639K	Hold	137,400	–	–	0.01%	1028
2020 Q4	$453K	Buy	137,400 +34,500	+34%	+$131K	0.01%	983
2020 Q3	$341K	Sell	102,900 -16,300	-14%	-$59.9K	0.01%	1018
2020 Q2	$402K	Buy	119,200 +75,500	+173%	+$357K	0.01%	931
2020 Q1	$167K	Sell	43,700 -50,000	-53%	-$232K	﹤0.01%	1106
2019 Q4	$566K	Buy	93,700 +13,200	+16%	+$90.3K	0.01%	924
2019 Q3	$609K	Hold	80,500	–	–	0.01%	871
2019 Q2	$1.09M	Hold	80,500	–	–	0.01%	710
2019 Q1	$436K	Buy	80,500 +25,000	+45%	+$122K	0.01%	1060
2018 Q4	$165K	Hold	55,500	–	–	﹤0.01%	1248
2018 Q3	$453K	Hold	55,500	–	–	﹤0.01%	1167
2018 Q2	$541K	Buy	55,500 +6,500	+13%	+$66.6K	0.01%	1109
2018 Q1	$426K	Hold	49,000	–	–	﹤0.01%	1134
2017 Q4	$613K	Hold	49,000	–	–	0.01%	1033
2017 Q3	$410K	Hold	49,000	–	–	﹤0.01%	1141
2017 Q2	$832K	Hold	49,000	–	–	0.01%	895
2017 Q1	$985K	Sell	49,000 -9,000	-16%	-$179K	0.01%	822
2016 Q4	$904K	Hold	58,000	–	–	0.01%	860
2016 Q3	$757K	Buy	+58,000	New	+$551K	0.01%	912

Other funds holding ZYNE

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Crystalline Management Montreal, Quebec, Canada $112M AUM 21.13% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bridgeway Capital Management's ZYNE Position: Q3 2023 in Review

Bridgeway Capital Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q3 2023, closing a stake of 65,900 shares — an estimated $21.5K sold.

Bridgeway Capital Management first reported a position in ZYNE in Q3 2016 and held it in 28 quarters. The position peaked at $1.09M in Q2 2019. 43 funds tracked by Wall St. Rank hold ZYNE as of Q3 2023.

Bridgeway Capital Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q3 2023 after selling out during the quarter.
Bridgeway Capital Management sold 65,900 Zynerba Pharmaceuticals, Inc shares in Q3 2023, an estimated $21.5K.
Bridgeway Capital Management first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 28 quarters.
Bridgeway Capital Management's Zynerba Pharmaceuticals, Inc position peaked at $1.09M in Q2 2019.
43 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q3 2023.

Based on Bridgeway Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.